Articles
3 June 2009
Vol. 1 No. 9: 3rd International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, October 14-16, 2005
https://doi.org/10.4081/hmr.v1i9.319

Low molecular weight heparin and survival in cancer

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
176
Views
174
Downloads

Authors

AK Kakkar
support@pagepress.org
More recent clinical trials have evaluated the potential benefits of low molecular weight heparin therapy in prolonging survival in patients with solid tumour malignancy. The Fragmin Advance Malignancy Outcome Study (FAMOUS) randomised 385 patients to receive the low molecular weight heparin dalteparin sodium (5000 units once daily) or normal saline placebo injections for up to 1 year. Patients in this trial had advanced disease (locally advanced or disseminated). The primary endpoint of this study was mortality one year after randomisation. 46% of dalteparin patients compared to 41% of placebo group patients were alive at 1 year (p=n.s). In a post-hoc sub-group analysis of good prognosis patients (n=102) dalteparin administration was associated with an increase of median survival from 24 months in the placebo group to 43 months in the dalteparin group.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Low molecular weight heparin and survival in cancer. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(9). https://doi.org/10.4081/hmr.v1i9.319